Sandeep Chandra, MD
Interventional Cardiology · Tucker, GANPI 1093801029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 628 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations.
Across 628 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Novartis$1K
- Amgen$1K
- Novo Nordisk$946
- AstraZeneca$675
- Pfizer$613
- plus $5K from 31 others
Across 68 payments — averaging $1580.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$59K
- Boehringer Ingelheim Pharma GmbH & Co.kg$23K
- Boehringer Ingelheim International GmbH$14K
- Sanofi US Services Inc.$11K
What the payments were for
- Food & beverage$11,03396%
- Education$4174%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 115 | $1,671 |
| Novartis | 75 | $1,258 |
| Amgen | 68 | $1,150 |
| Novo Nordisk | 53 | $946 |
| AstraZeneca | 34 | $675 |
| Pfizer | 34 | $613 |
| GSK | 34 | $540 |
| Boehringer Ingelheim | 29 | $522 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $520 |
| E.r. Squibb & Sons, L.L.C. | 31 | $477 |
| Esperion Therapeutics, Inc. | 20 | $380 |
| Astellas Pharma US Inc | 5 | $366 |
| Merck | 19 | $344 |
| Sanofi-aventis U.S. LLC | 13 | $238 |
| Amarin Pharma, Inc. | 13 | $233 |
| Azurity Pharmaceuticals, Inc. | 10 | $188 |
| Lilly USA, LLC | 11 | $186 |
| Boston Scientific | 3 | $178 |
| Actelion Pharmaceuticals US, Inc. | 3 | $166 |
| Baxter Healthcare | 3 | $150 |
| Regeneron Healthcare Solutions, Inc. | 6 | $111 |
| Alnylam Pharmaceuticals Inc. | 5 | $108 |
| Lundbeck LLC | 4 | $92 |
| Edwards Lifesciences | 3 | $79 |
| Gilead | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| Bardy Diagnostics, Inc. | 1 | $24 |
| Aegerion Pharmaceuticals, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Cleerly, Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$139
- UPTRAVI$125
- OPSUMIT$125
How this compares
$11,450 in reported general payments places this provider in the 60th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 606 | $676,052 |
| ArcalystRilonacept | 16 | $354,973 |
| XareltoRivaroxaban | 222 | $252,754 |
| EntrestoSacubitril/Valsartan | 157 | $202,055 |
| MounjaroTirzepatide | 121 | $179,163 |
| Repatha SureclickEvolocumab | 138 | $132,040 |
| JardianceEmpagliflozin | 85 | $106,085 |
| OzempicSemaglutide | 96 | $94,137 |
| FarxigaDapagliflozin Propanediol | 67 | $70,156 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $58,273 |
| TrulicityDulaglutide | 29 | $31,804 |
| Praluent PenAlirocumab | 45 | $29,401 |
| VascepaIcosapent Ethyl | 37 | $24,776 |
| JanuviaSitagliptin Phosphate | 14 | $18,123 |
| NexletolBempedoic Acid | 15 | $16,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $613 | $676,052606 claims |
| Johnson & JohnsonXarelto | $1,671 | $252,754222 claims |
| Lilly USA, LLCMounjaro, Trulicity | $186 | $210,966150 claims |
| NovartisEntresto | $1,258 | $202,055157 claims |
| Boehringer IngelheimJardiance, Tradjenta | $522 | $112,05897 claims |
| Novo NordiskOzempic | $946 | $94,13796 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $675 | $84,81798 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $540 | $77,036111 claims |
| MerckJanuvia | $344 | $18,12314 claims |
| Esperion Therapeutics, Inc.Nexletol | $380 | $16,72515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Tucker
- Zakaria AlmuwaqqatTucker$70K
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Mudassar AhmedGainesville$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.